AstraZeneca PLC (ZEG:F) Annual Income Statement ()
ZEG:F Quarterly Financials ()
Frequently Asked Questions About AstraZeneca PLC (ZEG:F) Stock
AstraZeneca PLC's (ZEG:F) last reported annual revenue was EUR 45.81 Billion.
AstraZeneca PLC's (ZEG:F) annual revenue growth rate based on the revenue reported in the past 5 years is : 15.71%
AstraZeneca PLC's(ZEG:F) is profitable as of its last reported annual financials.
The net profit margin for AstraZeneca PLC's(ZEG:F) from its laster reported year is 13.00%
The return on equity (ROE) for AstraZeneca PLC's(ZEG:F) from its last reported annual financials is : 15.64%
The return on assets (ROA) for AstraZeneca PLC's(ZEG:F) from its last reported annual financials is : 6.60%
The return on invested capital (ROIC) for AstraZeneca PLC's(ZEG:F) from its last reported annual financials is : 13.22%
The Debt to Equity ratio for AstraZeneca PLC's(ZEG:F) from its last reported annual financials is : 57.14%
The dividend yield for AstraZeneca PLC's(ZEG:F) from its laster reported year is 2.02%
AstraZeneca PLC's(ZEG:F) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ZEG:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
